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Background: Rationalization of antiangiogenics requires biomarkers. Vascular re-
normalization is one widely accepted mechanism of action for this drug class. The inter-
stitium of tumors with abnormal vasculature is hypoxic. We sought to track vascular
normalization with 18F-misonidazole ([18F]-FMISO, a probe that detects hypoxia) PET, in
response to window-of-opportunity (WoO) treatment with the antiangiogenic dovitinib.
Methods: Two patient-derived pancreas xenografts (PDXs; Panc215 and Panc286) and the
spontaneous breast cancer model MMTV-PyMT were used. Animals were treated during 1
week of WoO treatment with vehicle or dovitinib, preceded and followed by [18F]-FMISO-
PET, [18F]-FDG-PET, and histologic assessment (dextran extravasation, hypoxia and mi-
crovessel staining, and necrosis, cleaved caspase-3 and Ki67 measurements). After WoO
treatment, gemcitabine (pancreas)/adriamycin (breast) or vehicle was added and animals
were treated until the humane endpoint. Tumor growth inhibition (TGI) and survival were
the parameters studied.
Results: [18F]-FMISO SUV did not change after dovitinib-WoO treatment compared to
vehicle-WoO (0.54 vs. 0.6) treatment in Panc215, but it decreased significantly in Panc286
(0.58 vs. 1.18; P < 0.05). In parallel, 10-KDa perivascular dextran extravasation was not
reduced with dovitinib or vehicle-WoO treatment in Panc215, but it was reduced in
Panc286. Whereas the addition of dovitinib to gemcitabine was indifferent in Panc215, itcal Research Unit, CNIO e Spanish National Cancer Research Center, Melchor Fernandez
17 328 000x2930; fax: þ34 912 246 931.
uintela-Fandino).
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M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 0 4e7 1 8 705increased TGI in Panc286 (TGI switched from 59% to þ49%). [18F]-FMISO SUV changes
were accompanied by an almost 100% increase in interstitial gemcitabine delivery
(665e1260 ng/mL). The results were validated in the PyMT model.
Conclusions: [18F]-FMISO accurately monitored vascular re-normalization and improved
interstitial chemotherapy delivery.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction areas of the tumor are poorly irrigated and hypoxic (HlatkyAntiangiogenic agents are the most widely used biologic
agents for routine care in oncology. Positive randomized phase
III trials have led to FDA approval of different antiangiogenics
in most epithelial malignancies. However, for those malig-
nancies for which the drug class is approved and for those
for which the results are not yet conclusive, there is room for
improvement, especially regarding development of biomarker
and/or predictive factors to rationalize therapeutic resources.
The precise mechanism of action for this drug class is not
completely understood. The concept of antiangiogenesis has
evolved much since Folkman’s hypothesis (Folkman, 1971)
which proposed that tumorswould not be able to growbeyond
w0.1 mm if the development of novel blood vessels was abro-
gated. Novel antiangiogenics inhibit several proangiogenic
factors, as opposed to the VEGF-specific agent bevacizumab.
However, tumors still escape and develop resistance to novel,
multi-targeted agents (Limaverde-Sousa et al., 2014). Active
preclinical research has discoveredmore than a dozen factors
and receptors involved in angiogenesis that can interact in
hundreds of different potential ways due to the multi-
specificity of receptors and factors, triggering a plethora of
downstream physiopathologic effects (Lawler and Lawler,
2012; Petrillo et al., 2012; Richey and Hutson, 2013; Sakurai
and Kudo, 2011; Yan et al., 2014). This high number of fac-
tors/receptors makes complete pharmacologic angiogenesis
inhibition unrealistic. However, during the discovery of the
complex temporal and spatial regulation of the angiogenesis
process, one of the most relevant hypotheses regarding the
mechanism of action of this drug classdvascular normaliza-
tiondwas developed (Jain, 2005, 2013b): the equilibrium be-
tween proangiogenic and antiangiogenic factors that
maintain vessel homeostasis in normal tissues is deranged
in cancer. This equilibrium has to be maintained within tight
limits to generate normal blood vessels (Jain, 2005, 2013b;
Kerbel, 2006). The disruption of the equilibrium in the tumor
microenvironment leads to abnormal vessels. Abnormal tu-
mor vessels are highly fenestrated, tortuous, and permeable;
blood flow can be erratic, stagnant and/or retrograde instead
of unidirectional and constant. Together with abnormal
development and function of the drainage systems, these fac-
tors lead to increased interstitial pressure and intercellular
matrix edema (Jain, 2013b). In addition, the maximum dis-
tance between vessels and cells is heterogeneous and variable
(Hlatky et al., 2002; Jain, 2005, 2013b; Kerbel, 2006). Heteroge-
neous tumor cell subpopulations with different cell growth
andmetabolic rates have varying demands for oxygen and nu-
trients from the blood vessels (Hlatky et al., 2002). Thus, largeet al., 2002; Jain, 2005, 2013b; Kerbel, 2006). Hypoxia itself is a
tumor progression factor (Gilkes et al., 2014). Vascular abnor-
mality, characterized by impaired blood supply and intersti-
tial hypertension, interferes with the delivery of (chemo)
therapeutics to solid tumors (Jain, 2005, 2013b; Kerbel, 2006).
This situation can be reached by an excess or by a deficit of
proangiogenic or antiangiogenic factors in the tumor micro-
environment (Jain, 2005, 2013b; Kerbel, 2006). According to
this theory, when an antiangiogenic agent is administered,
this abnormal balance could be restored to almost normal
levels, and vasculature can be “re-normalized” (Jain, 2005,
2013b; Kerbel, 2006). Subsequently, chemotherapy delivery
would be improved. The hypothesis is plausible because anti-
angiogenic agents alone have no effect onmost epithelial ma-
lignancies (apart from non-liver, non-kidney cancers)
(Cobleigh et al., 2003; Yang et al., 2003). However, when added
to chemotherapy, the response rate is usually much higher
than that reported for chemotherapy alone (Burger et al.,
2011; Hurwitz et al., 2004; Miller et al., 2007; Perren et al.,
2011; Sandler et al., 2006).
This hypothesis also has drawbacks. First, the duration of
this normalization response is probably limited and could be
followed by vascular pruning; an inadequate vascular network
would interfere with chemotherapy delivery (Jain, 2005, 2013b;
Kerbel, 2006). Second, some antiangiogenics have been
demonstrated to normalize the vasculature and hypoxia,
whereas others have been shown to induce the opposite ef-
fect. A particularly striking study in that sense was performed
by Smit and Van der Veldt, in which radio-labeled docetaxel
was administered before and after bevacizumab to lung can-
cer patients and traced with a positron emission tomography
(PET) scan. In this study, tumor-docetaxel intake significantly
decreased after bevacizumab dosing, highlighting the impor-
tance of adequate chemo-antiangiogenic scheduling (Van der
Veldt et al., 2012). Third, there are many different approved
antiangiogenic agents with specificity against different targets
(and different Km against each). Each tumor has a unique
equilibrium between proangiogenic and antiangiogenic fac-
tors that is dynamic over time; hence, the interaction between
the drug and one tumor’s proangiogenic/antiangiogenic fac-
tors may not push the balance in the same direction as in a
different one. Thus, it is unlikely that a general statement or
model will work for every case. Therefore, personalized case-
by-case evaluations should be undertaken.
We hypothesized that tracing the status of vascular
normalization could be a realistic option for personalized de-
cisions. We sought to establish the proof-of-principle that 18F-
fluoromisonidazole-PET ([18F]-FMISO-PET) can detect in
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parallel, the amount of chemotherapy being delivered to the
tumor is increased. Although not all tumors show the same
vascular normality/abnormality status, and although this sta-
tus may change with time, what seems clear is that when the
vasculature is abnormal, the interstitial tissue is hypoxic, sec-
ondary to the increased interstitial pressure and edema. If
hypoxia could be accurately tracked, then so could vascular
abnormality. [18F]-FMISO is a fluorine-labeled, positron-emit-
ting nitroimidazole. After systemic infusion it is reduced and
binds to macromolecules within hypoxic cells. It diffuses
across cell membranes, showing a passive distribution
pattern. At 3 h after infusion, it remains bound only to hypoxic
areas, which allows their detection by PET (Bruehlmeier et al.,
2004). Baseline and dynamic assessments of tumor hypoxia
have shown prognostic correlations in lung and head and
neck cancer patients (Eschmann et al., 2005; Gagel et al.,
2006; Rischin et al., 2006b). We aimed to test the role of
[18F]-FMISO as a potential tracer of vascular normalization.
We believe it could be of potential use as a biomarker in the
context of antiangiogenic therapy.
Dovitinib is a multi-targeted tyrosine-kinase inhibitor with
activity against VEGFR1-3, PDGFRB, and FGFR1-3 that has
shown promising preclinical activity in a wide range of tu-
mors. In preclinical models it has demonstrated the capacity
for decreasing microvascular density and blocking angiogen-
esis (Huynh et al., 2012; Lee et al., 2005), because the endothe-
lium is its primary target (Chen et al., 2012). Its vascular-
normalizing properties have not been determined, but it is un-
dergoing clinical development for several malignancies. Dovi-
tinib has shown promising activity in preliminary clinical
trials, and thus we chose it for our proof-of-concept study.
Taking advantage of a window-of-opportunity (WoO)
design, we sought to study whether hypoxia tracing would
actually detect the event of vascular re-normalization across
different tumors (patient-derived xenografts, PDXs), and
whether this phenomenon would be followed by increased
interstitial chemotherapy delivery. Controversy exists
regardingwhether xenografts are excessively prone to develop
hypoxia when exposed to antiangiogenics compared to spon-
taneous cancer models (Franco et al., 2006), and thus not be a
perfect model for vascular normalization. Thus, we validated
our findings in a genetically engineered mouse model
(GEMM) of spontaneous breast cancer.2. Material and methods
2.1. Mouse models, treatments, and study design
Four-week-old female athymicnudemicewerepurchased from
Charles River Laboratories (Barcelona, Spain). PyMT [FVB/N-
Tg(MMTV-PyVT)634Mul/J] mice were obtained from W. Muller
(McMasterUniversity,Ontario,Canada).All animalsweremain-
tained at a constant temperature (24  0.5 C) under a 12-hour
light/dark cycle. All animal experiments were approved by the
CNIO Ethics Committee and performed in accordance with
the guidelines stated in the International Guiding Principles
for Biomedical Research Involving Animals developed by the
Council for International Organisations of Medical Sciences.Patient-derived xenografts (PDX) Panc215 and Panc286
were established and expanded as described previously
(Rubio-Viqueira et al., 2006). Tumors from passages 7 and 8
were used for this study.
Gemcitabine hydrochloride (Sigma Aldrich) was freshly
prepared in saline and administered at 100 mg/kg per day
intraperitoneally twice per week. Dovitinib was freshly pre-
pared in water with a pH of 2.5 and administered at 40 mg/
kg per day by oral gavage from days 1e28 and at 20 mg/kg
per day subsequently. This dose reduction was undertaken
since after 6 weeks of continuous dovitinib administration it
was common to observe weight loss (>10%) and vestibular
toxicity in approximately 25% of the animals of the combina-
tion groups (less frequently, but still observed, in the dovitinib
monotherapy animals). By reducing dovitinib to 20 mg/kg af-
ter 4 weeks, we did not observe incidence of this toxicity.
Gemcitabine was maintained unchanged, since we did not
observe signs of cumulative toxicity alone or in combination.
Adriamycin was dissolved in PBS and administered at 4mg/kg
intraperitoneally daily for 5 days during the first week.
The study design was a WoO followed by randomized
treatment (Figure 1A) (vehicle or dovitinib with or without
gemcitabine for the pancreas PDXs, or vehicle, or dovitinib
with or without adriamycin for the PyMT animals).
2.2. Tumor measurements and treatment endpoints
Mice were treated until at least one tumor reached approxi-
mately 1500mm3 (humane endpointmandating sacrifice). Tu-
mor dimensions were measured twice per week using a
caliper, and volumes were calculated using the following for-
mula: V ¼ (D  d2)/2 mm3, where D is the largest diameter and
d is the shortest diameter. All tumors were measured in one
animal and then averaged.
The endpoints under study were tumor growth inhibition
(TGI) and overall survival. The first parameter was calculated
by using the following formula: TGI ¼ [1  (TF/T0)A/(TF/
T0)V]  100, where TF is the tumor volume at the time point
analyzed, T0 is the tumor volume at the initial time, A is the
drug or combination undergoing study, and V is vehicle. In or-
der to estimate the overall survival, the dates of treatment
start and animal sacrifice (because of reaching the humane
endpoint or toxicity) were recorded for each animal; with
these values, KaplaneMeier survival plots were performed
(Section 2.6).
2.3. PET-CT imaging studies
Animalswere scanned on a small-animal PET scanner (ARGUS
PET-CT, SEDECAL, Madrid, Spain) under 3% isoflurane anes-
thesia. For 2-deoxy-2-18F-fluoro-D-glucose ([18F]-FDG),
0.6 mCi was injected into the tail vein and, after an uptake
period of 40 min, animals were scanned for 45 min. For
[18F]-FMISO-PET, [18F]-FMISO (0.8 mCi) was injected into the
tail vein; after an uptake period of 3.5 h, animalswere scanned
for 40 min. Both tracers were synthesized by ITP (Instituto
Tecnologico PET, Madrid), using an IBA Cyclone C18 cyclotron
equipped with an IBA Synthera V2 module with HPLC. Images
were reconstructed using a 2D ordered subset expectation
maximization algorithm. A tumor region of interest was
Figure 1 e Treatment schedule and hypoxia evolution during the WoO in pancreas PDXs. (A) Animals were treated during a 5-day window-of-
opportunity (WoO) and randomized to either vehicle or dovitinib to assess hypoxia evolution ([18F]-FMISO) and glucose uptake ([18F]-FDG-
PET). Treatment groups were set to harvest tumor material for staining microvessels and pimonidazole and for studying dextran extravasation
before and after the WoO. Subsequently, the animals were randomized to receiving added gemcitabine or not. Hypoxia evolution by [18F]-
FMISO-PET is shown during the WoO of (B) Panc215 and (C) Panc286. Number of tumors assessed per timepoint and condition: Panc215-T0:
11 tumors (6 animals); Panc215-Vehicle-Tend: 9 tumors (5 animals); Panc215-Dovitinib-Tend: 11 tumors (6 animals); Panc286-T0: 12 tumors (6
animals); Panc286-Vehicle-Tend: 9 tumors (5 animals); Panc286-Dovitinib-Tend: 9 tumors (5 animals), Representative scan images are provided.
*P < 0.05 (ANOVA-Bonferroni); error bars: standard error.
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tions. The PET data assessment included the analysis of the
mean and maximum standard uptake values (SUVmean and
SUVmax) in the tomographic study. The maximum SUV was
the parameter studied for [18F]-FDG. Regarding [18F]-FMISO,
the mean SUV was used according to the study by Eschmann
et al (Eschmann et al., 2007).2.4. Histology and immunohistochemistry
Depending upon the procedure, tumors were fixed in 10%
formalin solution, embedded in paraffin, and snap-frozen in
isopentane or OCT-embedded for cryopreservation.
Haematoxylin and eosin (H&E) staining was performed
according to standard procedures on 3-mm paraffin sections.
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SP6, Master Diagnostica, Granada, Spain). Cleaved caspase-
3 (CC3) was determined with a rabbit antibody from Cell
Signaling.
Pimonidazole staining was performed with Hypo-
xyprobe-1 Plus kit (HPI Inc, Burlington, MA). Pimonidazole
was administered intravenously at 60 mg/kg and tumors
were harvested 60 min later. Hypoxyprobe-1 adducts were
detected using an affinity-purified rabbit IgG polyclonal anti-
body conjugated with horseradish peroxidase following the
manufacturer’s instructions. Endothelial cells were detected
with a rabbit polyclonal antibody against CD31 (Abcam, Cam-
bridge, UK) andwere solvedwith a DBA-conjugated secondary
antibody. Tumor tissue hypoxia was quantified as follows: an
expert pathologist counted the number of cells positive and
negative for pimonidazole staining in three 20X representa-
tive fields per slide of three different tumors per timepoint
and condition. The evaluated areas included only viable
epithelial tissue, and excluded apoptotic areas, stromal-rich
areas, or necrotic areas. The scores for each timepoint and
condition are presented as percentage of cells positive for
pimonidazole.
Slides were scanned at 20X magnification. Digital images
were analyzed and quantified with an automated scanning
microscope equipped with an image analysis system (Ariol
SL-50 with Genetix vs. 3.4.). Necrotic areas were identified
and manually drown by an expert pathologist in a minimum
of five 4X fields per slide, in three slides per experimental con-
dition; the software calculated the percentage of the analyzed
areas that the necrotic areas constituted. Ki67-positive cells,
CC3-positive cells, hypoxic and vessel areas were computed
to be detected and quantified as percentage of positive cells
or percentage of total viable tissue area, by examining a min-
imum of five 10X fields (Ki67, CC3) or 4X fields (hypoxic areas
and vessels).
The dextran-extravasation protocol was performed as
follows. Animals were injected intravenously (tail vein)
with 10 KDa dextran conjugated with Texas-Red fluores-
cent dye 90 min before sacrifice. Tumors were harvested
and fixed in 10% formalin solution, embedded in a gradient
of sacarose (15% and 30%), embedded in OCT, snap-frozen
in isopentane, and stored at 80 C. Then, 30-mm-thick
frozen slides were stained with anti-CD31 antibody (Abcam)
and revealed with secondary antibody (Alexa Fluor 488 goat
anti-rabbit IgG, Molecular Probes, Carlsbad, CA). Mounted
slides were analysed by confocal microscopy. Six random
pictures per tumor were taken at 50 magnification. Quanti-
tation was performed with the Definiens Developer XD soft-
ware. Dextran extravasation was expressed as the average
area of Texas-Red staining (pixels) divided by the area of
blood vessels (CD31-positive pixels) plus the Texas-Red-
positive pixels of five random 40X-fields per tumor from
four tumors per timepoint and condition. A value close to
1 indicates important extravasation of the dextran, whereas
a value close to 0 indicates that most of the dextran stayed
inside the blood vessels or simply has abandoned the tumor
as a result of efficient blood flow and lack of blood vessel
leakiness. Regarding adriamycin, it was excited with an
argon laser at 488 nm; the emission was collected at the
535e600 nm window.2.5. Intratumoral gemcitabine determination
Calibration standards for gemcitabine were prepared in a 50/
50 mixture of acetonitrile and aqueous tetrahydrouridine
(THU, Merck Millipore; 200 mg/mL) at concentrations of 25,
50, 75, 100, 250, 500, 750, and 1000 ng/mL. Tumor samples
were prepared for gemcitabine analysis by taking 50 mL of
the sonicated sample and mixing with 50 mL of MilliQ ultra-
purewater. The sampleswere further diluted (1 in 10) for gem-
citabine analysis.
Ultraperformance liquid chromatography was performed
on a Waters (Milford, MA) iClass Acquity system using a
Kinetex C18 (Phenomenex, Torrance, CA) analytical column
(150  2.1 mm). Mobile phase A included 10 mM ammonium
acetate (pH 6.7). Mobile phase B included acetonitrile.
The compounds were eluted isocratically using the 80/20
mix of mobile phases A and B. The column temperature was
30 C. Mass spectrometry was performed on aWaters TQ-S tri-
ple quad mass spectrometer with electrospray ionization. It
was operated in positive ion mode for gemcitabine at a source
temperature of 150 C, with desolvation temperature of 650 C,
desolvation gas flow of 800 L/h, capillary voltage of 1.0 kV,
source offset of 40 V, cone voltage of 40 V, cone gas flow of
150 L/h, collision energy of 25 V, and collision gas flow of
0.15 mL/min. Data were processed using Waters UNIFI soft-
ware. Transitionsmeasuredwerem/z 263.9 to 112 for gemcita-
bine. Linear regression and 1/x2 weighting were used for
gemcitabine determination.
2.6. Data analysis and statistics
Statistical analysis was performed using SPSS Statistics
version 19. Data are shown as mean  SEM. Percentages
were compared with Z-tests. For TGI comparisons, student t-
test was used for two-group comparisons; three-group com-
parisons were performed by one-way analysis of variance
with Bonferroni test for pairwise comparisons. TGI values
were compared at the last timepoint in which the shortest-
survival group among those compared still remained animals
alive. That timepoint was always the last timepoint plotted in
the charts, except for comparisons including vehicle-treated
animals in Panc215 (because all the animals were dead at
the end of week 2) and comparisons including vehicle-
treated animals in the PyMT model (because all animals
were dead at the end of week 6). Two-tailed P < 0.05 was
considered significant.
The effects of the different treatments in animal survival
were estimated with the KaplaneMeier method and the Log-
Rank test. When an animal was sacrificed because of reaching
the humane endpoint, it was coded as an event. When an an-
imal was sacrificed because of toxicity or tumor-unrelated
causes (infection, animal manipulation, dead in cage,
etcetera) it was coded as a censured observation. The observa-
tion time for each animal lasted from treatment start until
sacrifice. Panc286 animals and PyMT animals were followed
until all animals required sacrifice because of tumor growth
(with the random exceptions of censured events). Panc215
experiment was terminated as two of the treatment groups
(gemcitabine and gemcitabine plus dovitinib) showed no
visible tumors after 4 weeks of treatment and no visible
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additional weeks of observation.3. Results
3.1. Baseline hypoxia, hypoxia modulation by dovitinib,
and sensitivity to gemcitabine
We started by tracking hypoxia evolution in the pancreas
PDXs. Baseline hypoxia, measured with [18F]-FMISO, was
similar in both models (Figure 1B and 1C). Both showed a
considerably fast growth pattern (Figure 2A and 2B). However,
Panc215 did so without significantly increasing the [18F]-






































































Dv + gem (n=12) 
Figure 2 e Tumor growth of Panc215 and Panc286. The left charts indicat
vehicle, dovitinib, or gemcitabine, or both dovitinib and gemcitabine. The K
in the right panels. Error bars: standard error.SUV increased by >50% in the vehicle-treated animals in
this model. Interestingly, Panc215 was sensitive to gemcita-
bine, whereas Panc286 was not. Dovitinib alone was not effec-
tive in either of the models (Figure 2A and 2B), thus allowing
isolation of its potential effect as a vascular normalizing agent
without interference with tumor growth. The TGI for dovitinib
alone compared to vehicle was 24.0% in Panc215 (P¼ 0.14) and
4.5% in Panc286 (P ANOVA ¼ 1). Dovitinib abrogated hypoxia
development in Panc286 during WoO treatment (Figure 1C),
but it remained unchanged for the Panc215 group
(Figure 1B). In parallel with the abrogation of hypoxia develop-
ment, dovitinib combined with gemcitabine increased the
anti-tumor effects in the Panc286 model (Figure 2B). While
gemcitabine alone appeared to enhance tumor growth (it
caused a59.5%TGI, or, in otherwords, 59% increase in tumor






























Vh      Dv       Gem    Dv+Gem
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Vh     Dv     Gem   Dv+Gem
Vh              0.85    0.19     0.009
Dv                          0.4       0.68
Gem                                   0.075                                      
   
Log-Rank P Value
Log-Rank P Value
e the growth of the (A) Panc215 and (B) Panc286 PDXs treated with
aplaneMeier survival curves for the same treatment groups are shown
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 0 4e7 1 8710provided significant inhibition relative to the vehicle controls
[49.6% TGI; P-value (T-test) for gemcitabineþdovitinib versus
gemcitabine ¼ 0.02]. Conversely, although Panc215 was
already sensitive, the addition of dovitinib did not add any
further benefit to gemcitabine (Figure 2A) [TGIs: gemcitabine,
78.4%; gemcitabine plus dovitinib, 82.3%; P-value (T-test) for
gemcitabineþdovitinib versus gemcitabine ¼ 0.92]. The
KaplaneMeier estimates for median overall survival of the
different treatment groups yielded similar effects. Regarding
Panc215, the median overall survival times for vehicle- andA
Panc215 T0 Panc215 post Vh Pa
500 μm 500 μm
B
Panc286 T0 Panc286 post Vh
500 μm 500 μm
100 μm100 μm 100 μm
100 μm100 μm
Figure 3 e [18F]-FMISO tracks vascular normalization. In the upper panels
10 KDa dextran (red) is shown, either before treatment (left) or after the W
immunohistochemistry of pimonidazole (red) at the same timepoints (lower
change during the WoO regardless of whether vehicle or dovitinib is admi
represent, respectively, the ratio between the area positive for dextran (insid
blood vessels area (upper chart), and the percentage of cells positive for pi
dovitinib treatment induces a change in the microvasculature so that there is
represents this descent (P-ANOVA[ 0.004). In parallel, there is a correctio
and the values plotted in the chart. *Z-test P [ 0.016. Error bars: standardovitinib-treated groups were 17 and 21 days respectively,
whereas it was not reached for the other two groups (Log-
Rank P < 0.001). At 28 days, the tumors had virtually disap-
peared for the gemcitabine- and dovitinib plus gemcitabine-
treated animals; we observed the animals for 3 more weeks
and since no tumor re-growth was observed, the experiment
was terminated (Figure 2A). Finally, regarding Panc286, the
median overall survival times were 35 (vehicle), 27 (dovitinib),
38 (gemcitabine) and 52 (dovitinib plus gemcitabine) days









































































































, confocal staining of microvessels with CD31 (green) and perivascular
oO with vehicle (middle) or dovitinib (right). In parallel, we show the
panels). It can be appreciated how in Panc215 (A) there is virtually no
nistered. The hypoxic areas are not modified either. The charts
e and outside blood vessels) and the area positive for dextran plus the
monidazole (lower chart, P-ANOVA [ 0.88). (B) On the contrary,
no longer extravasation of dextran (right inset). The chart numerically
n of hypoxia, as evidenced by the decreased red-staining in the images
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Figure 4 e Decreased [18F]-FMISO uptake does not correspond to necrotic areas. [18F]-FDG-PET before and after the WoO with vehicle or
dovitinib plus quantitation of the maximum SUV (n [ 10 tumors) for (A) Panc215 or (B) Panc286. P [ 0.31 and 0.53, respectively (Bonferroni).
Thus, despite the lack of changes in viability or glucose avidity, [18F]-FMISO showed dovitinib-induced changes. Representative H&E images
during the WoO for (C) Panc215 and (D) Panc286, respectively, where necrosis has been marked with asterisks. The necrosis percentage was
quantified as total area in three independent tumor sections; this percentage was very low for Panc286. In both cases, it did not suffer significant
variations during the WoO (P [ 0.29 and 0.14, respectively; Bonferroni).
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Figure 5 e [18F]-FMISO tracks increased chemotherapy delivery and sensitivity secondary to vascular normalization. (A) Chart depicts the
intratumor concentration of gemcitabine recovered 5 min after injection from 215 to 286 PDXs, either after a WoO with vehicle (“post-Vh”) or
dovitinib (“post-Dv”). The numbers of tumors were 10, 8, 8, and 10 for 215 post-Vh, 215 post-Dv, 286 post-Vh, and 286 post-Dv, respectively (two
tumors were grafted per animal, but usually 1 or 2 tumors per group fail grafting). (B) Ki67 (left, upper) and CC3 (left, lower) percentages in
Panc215 after a single dose of vehicle following vehicle during the WoO (“Vh-Vh”) or a single dose of gemcitabine following vehicle during the
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normalization
The concept of vascular normalization establishes that the
increased effects of chemotherapy when combined with an
antiangiogenic agent are mediated by improved vessel func-
tionality. The extravasation of high-molecular-weight dex-
trans is a good parameter for monitoring vascular
abnormality (high extravasation means vascular abnormal-
ity).Wemonitored extravasation of 10 KDa Texas-Red dextran
in the proximity of blood vessels during WoO to determine if
[18F]-FMISO-PET was monitoring its evolution.
Perivascular dextran extravasation remained stable during
vehicle-WoO treatment in Panc215 (Figure 3A, upper panels
and chart) and Panc286 (Figure 3B, upper panels and chart).
Dovitinib, which was able to reduce [18F]-FMISO SUV in
Panc286, was able to reduce perivascular extravasation in
Panc286 duringWoO, but not in Panc215 (Figure 3A and 3B, up-
per panels and charts). Thus, [18F]-FMISO evolution mirrors
the extravasation of 10 KDa dextran in these two models.
We aimed to determine if hypoxia and dextran extravasa-
tion also followed parallel behavior at the microscopic level.
We co-stained pimonidazole (a probe that binds to areas
with <1% O2) and microvessels. The images shown in the
lower panels in Figure 3A and 3B suggest hypoxia reversion
(Figure 3B, lower) accompanies vessel normalization
(Figure 3B, upper); when vessels are not normalized
(Figure 3A, upper), hypoxia is not corrected (Figure 3A, lower;
Panc215). The percentage of cells positive for pimonidazole
remained stable (w15%) in Panc215 tumors from before to af-
ter the WoO, both in the vehicle- and dovitinib-treated ani-
mals. However, in Panc286 tumors, we observed a
statistically significant decrease in the hypoxic cells fraction
(25.6%e9.8%; P ¼ 0.016) in the dovitinib-treated animals.
Both pimonidazole and [18F]-FMISO are 2-nitroimidazole hyp-
oxia probes that bind to hypoxic tissue through the same
mechanism; thus it was expected that we obtained similar re-
sults with both techniques. However, it was necessarily to
validate that we could obtain with a non-invasive technique
the same readout as with pimonidazole, and thus, we had to
demonstrate that the external PET-imaging was adequately
capturing hypoxia changes at the microscopic level. Accord-
ing to these results, [18F]-FMISO-PET is tracking hypoxia, a
surrogate parameter of vascular normalization.
Finally, numerical assessment of microvessels does not
necessarily translate to vessel functionality or adequate
perfusion (i.e., vascular normalization), as pointed out by
Judah Folkman in 2002 (Hlatky et al., 2002). Although in that
work the risks of the assessment of microvessel density as a
potential parameter that could work as a biomarker of efficacy
of antiangiogenics were thoroughly discussed, this parameter
is commonly reported in studies and trials of antiangiogenics.
Dovitinib induced a slight, but statistically significant,
decrease in microvessel density during WoO treatment in
Panc286 (Figure S1). Conversely, the changes induced by eitherWoO (“Vh-Gem”), or after a single dose of vehicle or gemcitabine followin
Representative insets of Ki67 (right, upper) and CC3 (right, lower) stainin
right: Dv-Gem). (C) Same charts and insets for Panc286. *P < 0.05 (ANOvehicle or dovitinib in Panc215 did not reach statistical signif-
icance (Figure S1).
Taken together, these data suggest that [18F]-FMISO-PET
tracks the process of antiangiogenic-induced vascular
normalization during WoO treatment.
3.3. Specificity of [18F]-FMISO and tissue viability
Dovitinib could be inducing tumor necrosis secondarily to po-
tential vascular-pruning effects, which could affect the poten-
tial assessment of TGI. In addition, necrosis is not adequately
assessed by [18F]-FMISO (because [18F]-FMISO binding is
dependent on metabolic viability of the cells, and thus it
does not bind to necrotic areas (Bruehlmeier et al., 2004) e
hence, it would be difficult to know whether a decrease in
[18F]-FMISO uptake was caused by increased necrosis, or by
an increased normoxic tumor fraction that is not avid for
[18F]-FMISO). We aimed to confirm whether the signal
changes shown in Figure 1 corresponded to oxygenation
changes (and, thus, vascular normalization), or whether the
tissue simply became necrotic and the tracer was not profi-
cient in detecting this parameter.
We performed [18F]-FDG-PET during theWoO in both PDXs
(Figure 4A and 4B); as opposed to [18F]-FMISO, necrotic areas
can be detected by [18F]-FDG as “black” areas. It can be clearly
appreciated that the tissue is viable and glucose-avid in both
cases, with no meaningful changes over time with vehicle or
dovitinib treatment. We also determined the necrotic areas
with H&E staining and histologic evaluation. Again
(Figure 4C and 4D), we confirmed the lack of induction of ne-
crosis by antiangiogenic treatment during the WoO. We can
thus conclude that the changes in the [18F]-FMISO signals
were specific to viable tissue.
3.4. Normalized tumors tracked by [18F]-FMISO show
increased gemcitabine concentration and cell death in
response to gemcitabine
Cytotoxicity and/or chemo-sensitivity are multifactorial fea-
tures of epithelial malignancies. However, two important fac-
tors that influence chemo-sensitivity are the amount of drug
that is delivered and microenvironmental hypoxia. [18F]-
FMISO-PET seems to trace hypoxia (Figures 1 and 3). We also
measured interstitial gemcitabine in both tumor models. An-
imals harboring the Panc215 PDX were treated during the
WoO with either vehicle or dovitinib and then given a single
dose of gemcitabine. The average intratumor concentration
of gemcitabine (harvested 5 min after the injection) was virtu-
ally the same in both groups (1015 and 1089 ng/mL, respec-
tively; Figure 5A), showing that the lack of changes in [18F]-
FMISO signal and vascular normalization accompanied a
lack of changes in drug delivery. However, in the case of
Panc286, the results were different. After vehicle-WoO treat-
ment, the tumors had an average gemcitabine concentration
of 665 ng/mL, which almost doubled after dovitinib-WoOg dovitinib during the WoO (“Dv-Vh” and “Dv-Gem,” respectively).
g (upper left: Vh-Vh; upper right: Vh-Gem; lower left: Dv-Vh; lower
VA-Bonferroni); error bars: standard error.
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tracks vascular normalization and increased drug delivery in
the interstitium, which could explain the increased efficacy
of gemcitabine combinedwith dovitinib compared to gemcita-
bine alone in Panc286.
The Ki67 fraction decreased and the CC3 staining increased
after a single post-vehicle WoO-gemcitabine dose (compared
to baseline parameters) in the Panc215 PDX, but these param-
eters were not modified by the dovitinib-WoO (Ki67 and CC3
assessed 48 h after the gemcitabine dose). The single gemcita-
bine dose induced similar changes in Ki67 and CC3 (Figure 5B).
As expected, gemcitabine only modified these parameters af-
ter dovitinib priming (Figure 5C) in Panc286.
3.5. Validation in the PyMT genetically engineered
mouse model of breast cancer
It has been proposed that xenografts might be excessively
prone to develop hypoxia due to three factors: the fact that xe-
nografts grow subcutaneously and are poorly vascularized,
the lack of immune system (which is a main regulator of the
angiogenesis process), and the species mismatch between
stroma and parenchyma (Sharpless and Depinho, 2006).
Therefore, the vascular normalization phenomenon might
not work exactly the same as in spontaneous tumors
(Francia et al., 2011; Kerbel, 2011, 2012; Kerbel et al., 2013).
We sought to validate our findings in an independent model.
We backcrossed the MMTV-PyMT breast cancer model to a
pure FVB background which gave rise to ductal carcinoma in
situ of the breast at 4 weeks of age; at 7 weeks of age, 100%
of animals had invasive tumors thatwere, on average, approx-
imately 150 mm3 (Figure S2). When starting treatment at this
age, the tumors were resistant to adriamycin, the most widely
used chemotherapy agent against breast cancer (TGI adria-
mycin vs. vehicle: 2.8%; T-test P ¼ 0.74) (Figure 6A). Dovitinib
alone was able to induce significant effects in TGI (49.8%
TGI; P < 0.001). The combination of dovitinib plus adriamycin
was the most powerful; however, it only achieved statistical
significance for the comparison versus adriamycinmonother-
apy and not versus dovitinib alone (TGI of adriamycin plus
dovitinib: 63.5%; T-test P value for adriamycin versus adriamy-
cinþdovitinib <0.001; P value for dovitinib versus
adriamycinþdovitinib ¼ 0.16) (Figure 6A). In terms of animal
survival, the different treatment groups yielded the following
results: vehicle, 28 days; adriamycin, 35 days; dovitinib, 49
days; dovitinib plus adriamycin, 63 days (Log-Rank P < 0.001)
(Figure 6A). After the dovitinib-WoO, compared with vehicle,
[18F]-FMISO uptake was reduced by approximately 50%
(Figure 6B). [18F]-FMISO uptake mirrored hypoxia evolution
at the microscopic level (Figure 6C), showing how dovitinib
corrected this parameter. The percentage of cells positive for
pimonidazole was 30.6% in the vehicle-treated animals,
compared to 3.6% in the dovitinib-treated animals (Z-test
P < 0.001) (Figure 6C). The confocal images in Figure 6D
show how the delivery of adriamycin (which has the advan-
tage over gemcitabine of emitting red fluorescence) is
increased in the vascular/perivascular areas after the
dovitinib-WoO compared with vehicle. As opposed to large
molecules (i.e., 10 Kda dextrans), that, when present in the
perivascular areas indicate abnormal vessel function andpoor perfusion, the increased presence of small molecules in
the vascular/perivascular such as fluorescent lectins (or adria-
mycin) is indicative of improved perfusion (Rolny et al., 2011).
Finally, at a higher magnification, it can also be appreciated
how adriamycin is bound to the nuclei of cancer cells in the
dovitinib-treated animals (Figure S3, lower panels), as
opposed to the vehicle-treated tumors (S3, upper panels),
where the arrival of adriamycin to the nuclei is very poor.4. Discussion
Although there is previous work analyzing the perfusion
changes in response to antiangiogenic treatment (Ferl and
Port, 2012; Jain, 2013a), finding predictive factors or bio-
markers for the activity of antiangiogenic agents has been
an elusive task. Chemotherapy sensitivity is modulated by
co-administration of antiangiogenic drugs (Jain, 2005, 2013b;
Kerbel, 2006). According to the theory of vascular normaliza-
tion, tumors have abnormal vessels that impede adequate de-
livery of chemotherapy drugs (Jain, 2005, 2013b; Kerbel, 2006).
Antiangiogenics alone would not causemeaningful antitumor
effects, but rather would facilitate the delivery of chemo-
therapy and re-oxygenate the interstitium, which would also
increase the chemo-sensitivity (Jain, 2005, 2013b; Kerbel,
2006). Obviously, this would not occur in a uniform manner,
as evidenced by the fact that not all the patients enrolled in
chemotherapy plus antiangiogenic trials experience a clinical
response (Jain, 2008). In addition, contradictory reports exist
on whether antiangiogenics improve or deteriorate perfusion
(Van der Veldt et al., 2012). We proposed that because
abnormal blood vessels are accompanied by hypoxic intersti-
tium, tracking hypoxia would allow tracking vascular normal-
ization with an available noninvasive biomarker.
We show how the same antiangiogenic agent, dovitinib,
does not necessarily induce a homogeneous normalizing ef-
fect across tumors of the same type. In our study, dovitinib
was able to normalize Panc286 (Figure 3B), but not Panc215
(Figure 3A). The balance between proangiogenic and antian-
giogenic factors is specific to a given tumor in a givenmoment
and is dynamic in nature. It is not realistic to expect that two
tumors from two different patientswill have the same balance
and that they will be constant over time. In addition, the ef-
fects of a drug with pleiotropic effects (such as dovitinib,
with therapeutic effects in at least eight kinases) are the result
of the interaction of the drugwith the specific balance of a spe-
cific tumor and are probably difficult to predict. However, as
shown in Figures 1B, 1C, and 4, they seem traceable. What is
of key importance about tracing dovitinib effects is not hypox-
ia itself (although hypoxia is a tumor progression factor), but
rather the fact that hypoxia seems to be a surrogate parameter
of vascular abnormality. When hypoxia is reverted (Figures 1C
and 3B), so is abnormality (Figure 3B). What is more important
for the clinical applicability is that when this phenomenon oc-
curs, chemotherapy delivery is improved (Figure 5A) and cyto-
toxicity is enhanced (Figure 5C). Conversely, when hypoxia is
not corrected (Figures 1B and 3A), the abnormality is not
reverted (Figure 3A). In this situation, dovitinib does not
modify the amount of interstitial gemcitabine or cytotoxicity
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Log-Rank P Value
Figure 6 e Validation in the PyMT genetically engineered breast cancer model. (A) Tumor growth and survival of the PyMT tumors/animals in
response to the four treatments. (B) [18F]-FMISO suggests decreased hypoxia after a WoO with dovitinib compared to vehicle (T-test
P < 0.001). (C) Pimonidazole staining showing hypoxia evolution in response to dovitinib or vehicle plus quantitation chart (*Z-test P < 0.001).
(D) CD31 staining (left panels) is shown from representative tumors after the WoO with vehicle (up) or dovitinib (down). The number of vessels
decreases, and the vessel trajectory is less tortuous; also the vessel size is homogeneous and regular along the vessel course. On the right side, the
fluorescence captured by the red-light filter is shown. Interestingly, the bright signal characteristic of adriamycin is highlighted over the
background delineating the trajectory of blood vessels, indicating perfusion of the tumors and arrival of the agent. Conversely, no pattern can be
recognised in the upper panel. In order to facilitate the identification, the vessels are labelled as “V” and the corresponding areas with bright
adriamycin signal as “A” in the bottom panels. Error bars: standard error of the mean.
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M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 0 4e7 1 8716translation in TGI (Figure 2). Taken together, the results sug-
gest that [18F]-FMISO mirrors the combined evolution of hyp-
oxia and vascular normality/abnormality in response to short-
course antiangiogenic treatment. The results seem to be valid
both in the pancreas cancer PDXs and the breast cancer
GEMM. It is important to mention, however, that we have
not established a causal link between [18F]-FMISO signal
changes and chemo-sensitization. Sensitivity to chemo-
therapy is a complex phenomenon; many factors play a role
in chemosensitivity. Of those, chemotherapy concentration
is only one of them.We only provide proof-of-principle results
regarding how [18F]-FMISOmonitors the changes in the inter-
stitium that accompany vascular normalization, which, in our
models, was followed by increased chemotherapy delivery.
Increased chemotherapy delivery or concentration may or
may not be followed by increased tumor cell death, despite
the fact that we offer examples of a positive correlation
(Figure 5C). A causal link between [18F]-FMISO signal changes
and subsequent chemo-sensitization will only be possible to
establish when many tumor models, or, preferably, patients,
are analyzed.
TheWoO is not aimed to or sufficient to re-sensitize the tu-
mors to chemotherapy. Both the breast and the pancreas
models that were insensitive to adriamycin or gemcitabine
monotherapy but were sensitive to the combinations required
continuous treatment of chemotherapy plus dovitinib until
sacrifice. In fact, we tested treatment groups consisting on
dovitinib 5 days followed by vehicle plus chemotherapy, and
the results were virtually identical to vehicle plus chemo-
therapy groups (data not shown). The WoO is aimed to show
that the antiangiogenic is able to induce stromal changes
(decrease dextran extravasation, improved chemotherapy de-
livery, decrease hypoxia and improved vessel architecture),
and allows demonstrating that [18F]-FMISO-PET is able to
monitor these changes. The early detection of these changes
by [18F]-FMISO-PET may allow having available a tool with
predictive power in the clinical setting, regardless of whether
is the baseline hypoxia or the hypoxia levels after a few days
or at the end of the treatment course what predicts the sensi-
tivity e such information will only be answered within a clin-
ical trial. However, what seems reasonable is to state that
chemotherapy sensitivity requires vascular normalization
and chemotherapy delivery, and that [18F]-FMISO-PET is
able to indirectly detect that bymeasuring interstitial hypoxia.
Two important advantages of this type of testing are its
noninvasiveness and its quantitative nature in “real time.”
Baseline and dynamic assessment of tumor hypoxia have
shown prognostic correlation in lung and head and neck can-
cer patients (Eschmann et al., 2005; Rischin et al., 2006a). We
tested its role as a tool for tracing the positive effects of anti-
angiogenics. The results seem to be specific and not biased,
at least in this study, by necrotic tumor areas. The expression
of reductases can affect the binding of hypoxic probes in tis-
sues (Wang et al., 2012), but we did not find changes in CYPOR
reductase expression in tumors treated with dovitinib or
vehicle that could justify the different [18F]-FMISO uptake af-
ter the WoO in the different models (data not shown). An
obvious limitation of our study is that it needs to extend the
observations to further models and/or drugs, but we simply
aimed to provide proof of principle. According to ourhypothesis, the effects of a given antiangiogenic drug might
be normalizing in one tumor and “abnormalizing” in another;
similarly, two antiangiogenic drugs might exert different
normalizing/abnormalizing effects in the same tumor because
of their different affinities against various receptors. However,
the ultimate effects in the interstitium (normalization and, in
parallel, oxygenation) and its downstream consequences
(increased chemotherapy delivery) seem to be easily monitor-
able according to our study and should not depend upon the
agent used. A clinical trial with many patients will provide
stronger evidence to our proof-of-principle than further
mouse models. We have recently completed a randomized
clinical trial based upon this concept, and it is currently under-
going analysis. The patients were treated with a similar agent
(nintedanib); and a positive result in this trial would confirm
the hypothesis that vascular normalization can be traced in
an individual basis with [18F]-FMISO-PET.5. Conclusions
Although there is previous work evaluating the role of other
imaging techniques (mainly DCE-MRI) in predicting the
outcome of patients treated with antiangiogenics (Ferl and
Port, 2012; Jain, 2013a), unfortunately it is still complex to
incorporate such techniques in the daily-routine clinical
decision-trees. Since antiangiogenics may exert their positive
effect by normalizing the stroma, at least in some cases, and
abnormal stroma is characterized by hypoxia, we sought to
monitor hypoxia evolution in several tumor models exposed
to the antiangiogenic agent dovitinib. We demonstrate how
[18F]-FMISO-PET is able to detect when dovitinib is exerting
a positive effect in the stroma. When [18F]-FMISO-PET signal
decreases, so does tissue hypoxia. In parallel, the vascular
structures are normalized and the delivery of chemotherapy
(administered in combination with dovitinib) to the intersti-
tium increases, what is followed by increased tumor cell death
Thus, [18F]-FMISO-PET is a potential tool that could detect in
an individual basis when antiangiogenic tumors are inducing
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